What's new in the treatment of multidrug-resistant gram-negative infections? |
| |
Authors: | Yoonsun Mo Michael Lorenzo Sara Farghaly Kamaljit Kaur Seth T Housman |
| |
Institution: | 1. Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University Pharmacy, 75 Dekalb Avenue, Brooklyn, NY 11201-5497;2. Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01199;3. Department of Pharmacy Practice, Western New England University College of Pharmacy and Health Sciences, 1215 Wilbraham Road, Springfield, MA 01119 |
| |
Abstract: | Eradicating multi-drug resistant (MDR) organisms has been a major challenge in healthcare settings worldwide. Newly approved drugs and those currently in the pipeline may have a promising solution to this issue. The purposes of this review are to describe the various resistance mechanisms of Gram-negative bacteria and to provide a summary of the current literature available on the newer agents, such as ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and other emerging agents used for the treatment of MDR Gram-negative infections. Given that MDR organisms confer resistance to treatment by various methods, including enzymatic degradation, efflux pumps, and porin mutation, an understanding of mechanisms of bacterial resistance combined with information on newer antimicrobial agents against MDR Gram-negative bacteria will further assist clinicians in determining the best suitable therapy for the treatment of various complicated infections. |
| |
Keywords: | Multi-drug resistant Gram-negative bacteria New drug Antimicrobial drug resistance Carbapenemase |
本文献已被 ScienceDirect 等数据库收录! |
|